BACKGROUND: A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of response are lower in patients coinfected with HCV and human immunodeficiency virus (HIV), the recognition of predictors of response is a high priority in this population. METHODS: A baseline noninvasive index was derived on the basis of the probability of achieving sustained virological response in a group of 159 HIV-HCV-coinfected patients treated at one clinic in Spain. The index was then validated using data from a separate cohort of 86 coinfected individuals. Only individuals who had completed a course of pegIFN-RBV therapy and had validated outcomes were considered. RESULTS: The final score included 4 variables: 2 host-related variables (IL28B SNP rs12979860 and liver stiffness) and 2 HCV-related variables (genotype and viral load). The area under the receiver operating characteristic curve was 0.89 in the derivation group and 0.85 in the validation group. CONCLUSIONS: The probability of achieving sustained virological response with pegIFN-RBV therapy in HIV-HCV-coinfected patients can be reliably estimated prior to initiation of therapy using an index that includes 4 noninvasive parameters.
BACKGROUND: A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of response are lower in patients coinfected with HCV and human immunodeficiency virus (HIV), the recognition of predictors of response is a high priority in this population. METHODS: A baseline noninvasive index was derived on the basis of the probability of achieving sustained virological response in a group of 159 HIV-HCV-coinfectedpatients treated at one clinic in Spain. The index was then validated using data from a separate cohort of 86 coinfected individuals. Only individuals who had completed a course of pegIFN-RBV therapy and had validated outcomes were considered. RESULTS: The final score included 4 variables: 2 host-related variables (IL28B SNP rs12979860 and liver stiffness) and 2 HCV-related variables (genotype and viral load). The area under the receiver operating characteristic curve was 0.89 in the derivation group and 0.85 in the validation group. CONCLUSIONS: The probability of achieving sustained virological response with pegIFN-RBV therapy in HIV-HCV-coinfectedpatients can be reliably estimated prior to initiation of therapy using an index that includes 4 noninvasive parameters.
Authors: Norma I Rallón; Vincent Soriano; Susanna Naggie; Clara Restrepo; David Goldstein; Eugenia Vispo; John McHutchison; José M Benito Journal: AIDS Date: 2011-05-15 Impact factor: 4.177
Authors: A Rivero-Juarez; J A Mira; A Camacho; K Neukam; I Perez-Camacho; A Caruz; J Macias; J Torre-Cisneros; J A Pineda; A Rivero Journal: Infection Date: 2012-10-14 Impact factor: 3.553
Authors: María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino Journal: BMC Med Date: 2013-01-08 Impact factor: 8.775
Authors: Barham K Abu Dayyeh; Namrata Gupta; Kenneth E Sherman; Paul I W de Bakker; Raymond T Chung Journal: PLoS One Date: 2011-10-07 Impact factor: 3.240
Authors: Sara Corchado; Luis F López-Cortés; Antonio Rivero-Juárez; Almudena Torres-Cornejo; Antonio Rivero; Mercedes Márquez-Coello; José-Antonio Girón-González Journal: PLoS One Date: 2014-07-11 Impact factor: 3.240